This study will characterize the expression of toll-like receptors, which activate the immune system, in canine osteosarcoma cells to better determine the biological consequences associated with activating these receptors.

SUMMARY: Researchers will study whether a combination of oral medication and new tumor vaccine provide survival benefit for dogs diagnosed with osteosarcoma. THE PROBLEM: Osteosarcoma (OS) is the most common...

SUMMARY: Researchers will study chemoresistance in osteosarcoma cell lines to learn more about why this occurs and how it could be overcome. THE PROBLEM: Osteosarcoma is a highly aggressive bone...

Researchers will evaluate the safety and efficacy of a novel combination of checkpoint inhibitor and adoptive T-cell therapy in giant-breed dogs diagnosed with appendicular osteosarcoma, a type of primary bone cancer of the limbs.

Researchers are evaluating the effectiveness of oral rapamycin as an adjunct, postsurgery therapy to combat cancer spread (metastasis) in client-owned dogs.

Researchers will explore metabolic drivers of cancer growth and look for new therapy targets for osteosarcoma, the most common type of bone cancer in dogs.

This study will provide a molecular framework for understanding the process of miR-9-driven tumor spread in canine osteosarcoma, thereby generating potential new targets for therapy to prevent or treat tumor spread in this devastating disease.

Researchers will study how to block an immune protein associated with the accelerated spread of osteosarcoma in dogs.

SUMMARY: Researchers will investigate a new surgical limb-sparing technique.

Researchers are studying a group of 80 dogs with osteosarcoma to generate comparison data for ongoing and future studies of new chemotherapeutic agents.